Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group

Relapsed urothelial cancer represents an unmet medical need. Vinflunine is a third-generation antimicrotubuline inhibitor and is currently the only approved drug for second-line treatment across the European Union. We conducted a retrospective analysis assessing the efficacy and safety of vinflunine...

Descripción completa

Detalles Bibliográficos
Autores principales: Pistamaltzian, Nikolaos, Tzannis, Kimon, Pissanidou, Vassiliki, Peroukidis, Stavros, Milaki, Georgia, Karavasilis, Vasilis, Mitsogiannis, Iraklis, Varkarakis, Ioannis, Papatsoris, Athanasios, Dellis, Athanasios, Adamakis, Ioannis, Stravodimos, Konstantinos, Molyva, Dimitra, Athanasiadis, Ilias, Androulakis, Nikos, Andreadis, Charalambos, Kalofonos, Charalambos, Mitropoulos, Dionisios, Deliveliotis, Charalambos, Constantinides, Constantinos, Dimopoulos, Meletios A., Bamias, Aristotelis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885529/
https://www.ncbi.nlm.nih.gov/pubmed/26421462
http://dx.doi.org/10.1097/CAD.0000000000000297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885529/
https://www.ncbi.nlm.nih.gov/pubmed/26421462
http://dx.doi.org/10.1097/CAD.0000000000000297

Ejemplares similares